Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25747919 | 0.89 | MAPK14 (0.38) | MAPK14KDM4EMAPK1PRKAB2PRKAG1 | |
| SCHEMBL25438668 | 0.86 | ALDH1A1 (0.38) | MAPK14KDM4EMAPK1MTNR1AMTNR1B | |
| SCHEMBL31077755 | 0.86 | MAPK14 (0.47) | MAPK14KDM4EMAPK1PRKAB2PRKAG1 | |
| SCHEMBL25747875 | 0.86 | MAPK14 (0.47) | MAPK14KDM4EMAPK1PRKAB2PRKAG1 | |
| SCHEMBL25747925 | 0.82 | ALDH1A1 (0.41) | MAPK14KDM4EMAPK1PRKAB2PRKAG1 | |
| SCHEMBL25424702 | 0.81 | ALDH1A1 (0.40) | MAPK14KDM4EMAPK1PRKAB2PRKAG1 | |
| SCHEMBL25747942 | 0.81 | KDM4E (0.39) | MAPK14KDM4EMAPK1MTNR1AMTNR1B | |
| SCHEMBL31077720 | 0.81 | KDM4E (0.39) | MAPK14KDM4EMAPK1MTNR1AMTNR1B | |
| SCHEMBL25241421 | 0.80 | PRKAB2 (0.43) | KDM4EMAPK1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL31077782 | 0.80 | PRKAB2 (0.43) | KDM4EMAPK1PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | MAPK14 2602/4885KDM4E 3243/4885MAPK1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.